OssulinTM, A Novel Oral Insulin Product, Shows Promising Bioavailability For Advancing Diabetes Therapy

Main Category: Diabetes
Article Date: 10 Nov 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, CA, suggests that higher blood levels of insulin were achieved by Ossulin™ than had been previously demonstrated by other oral products. In a series of experiments covering a range of doses and models, Ossulin™ consistently delivered around 20% of the insulin dose into the bloodstream.

The authors concluded that:

"Ossulin provides an efficient way to deliver insulin to the body via oral administration, resulting in blood levels higher than those previously observed with other oral insulin products."

Lead author and Chief Scientific Officer for Puredel, Dr. Marco Prosdocimi added:

"Oral insulin could represent a major advance in diabetes therapy through its simplicity of use, and because it mimics the natural physiological route of the hormone. The incorporation of insulin into the proprietary delivery agent NatsomTM gives rise to a product which is not destroyed by the gastric environment."

Source
Puredel Limited

• Additional
• References
• Citations